Skip to Main Content

INFORMATION FOR

Anne Chiang, MD, PhD

Associate Professor; Associate Cancer Center Director, Clinical Initiatives

Research Summary

Dr. Chiang is the Deputy Chief Medical Officer and Chief Network Officer at Smilow Cancer Hospital. Her specialty is in thoracic oncology and she is involved in clinical research protocols specific to her patients with lung cancer. Her primary research focus is to develop new anti-cancer therapies for lung cancer patients. Dr. Chiang oversees network operations, quality efforts, and clinical research in 10 community locations. Additionally, she has a specialized focus in quality measurement and improvement, and has been an integral part of achieving the ASCO Quality Oncology Practive Initiative Certification for the entire Smilow academic clinical practice.

Coauthors

Research Interests

Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Lung Neoplasms; Small Cell Lung Carcinoma

Public Health Interests

Health Care Quality, Efficiency; Health Care Management

Selected Publications

  • EP16.02-002 Circulating Tumor DNA (ctDNA) Changes in Patients With Lung Cancer from a Real-World Prospective Clinico-Genomic (PCG) StudyChiang A, Kaur M, Assaf Z, Fine A, Zhao Y, Cao Y, Madison R, Oxnard G, Tolba K, Zuniga R, Lakhanpal S, Antic V, Bourla A, Schulze K. EP16.02-002 Circulating Tumor DNA (ctDNA) Changes in Patients With Lung Cancer from a Real-World Prospective Clinico-Genomic (PCG) Study Journal Of Thoracic Oncology 2022, 17: s571-s572. DOI: 10.1016/j.jtho.2022.07.1033.
  • A pilot study of ipilimumab and nivolumab in recurrent extensive-stage small cell lung cancer after platinum-based chemotherapy.Chiang A, Austin M, Stewart T, Arammash M, Bhatt S, Gettinger S, Goldberg S, Wilson F, Newton B, Cohenuram M, Sabbath K, Talsania A, Russo A, Herbst R, Schalper K. A pilot study of ipilimumab and nivolumab in recurrent extensive-stage small cell lung cancer after platinum-based chemotherapy. Journal Of Clinical Oncology 2022, 40: 8583-8583. DOI: 10.1200/jco.2022.40.16_suppl.8583.
  • KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer.Sands J, Reck M, Navarro A, Chiang A, Lu S, Peled N, Paz-Ares L, Kerr S, Takahashi T, Smolin A, Chen X, Zhao B, El-Osta H, Califano R. KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer. Journal Of Clinical Oncology 2022, 40: tps8606-tps8606. DOI: 10.1200/jco.2022.40.16_suppl.tps8606.
  • Plenary Session—The Patient Journey: Access to Cancer CareHammon D, Souza E, Chiang A, Shulman L, Kubal T. Plenary Session—The Patient Journey: Access to Cancer Care Journal Of The National Comprehensive Cancer Network 2022, 20: 1-4. DOI: 10.6004/jnccn.2022.5011.
  • “The waiting is the worst”: Development of a next day access (NDA) program for patients with cancer.Mougalian S, Shomsky L, Campos M, Chiang A. “The waiting is the worst”: Development of a next day access (NDA) program for patients with cancer. Journal Of Clinical Oncology 2021, 39: 205-205. DOI: 10.1200/jco.2020.39.28_suppl.205.
  • Therapeutic Advances in Small Cell Lung Cancer ManagementNewton B, Chiang A. Therapeutic Advances in Small Cell Lung Cancer Management 2021, 175-195. DOI: 10.1007/978-3-030-74028-3_8.
  • Implementing the cancer and aging research group (CARG) tool in the ambulatory oncology setting to drive informed treatment selection.Mbewe A, Pike P, Lewis R, Kortmansky J, Chiang A, Kanowitz J. Implementing the cancer and aging research group (CARG) tool in the ambulatory oncology setting to drive informed treatment selection. Journal Of Clinical Oncology 2021, 39: 209-209. DOI: 10.1200/jco.2020.39.28_suppl.209.
  • P09.55 A Platform to Prospectively Link Real-World Clinico-Genomic, Imaging, and Outcomes Data for Patients With Lung CancerWalia G, Lu M, Bourla A, Santos E, Schulze K, Cabili M, Williams E, Mirkovic N, Dicecca R, Lee S, Fang B, Schwartzberg L, Herbst R, Chiang A. P09.55 A Platform to Prospectively Link Real-World Clinico-Genomic, Imaging, and Outcomes Data for Patients With Lung Cancer Journal Of Thoracic Oncology 2021, 16: s316-s317. DOI: 10.1016/j.jtho.2021.01.483.
  • 359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim resultsBorghaei H, Boyer M, Johnson M, Govindan R, Rodrigues L, Blackhall F, Boosman R, Champiat S, Hummel H, Lai W, Udagawa H, Chiang A, Dowlati A, Hann C, Salgia R, Vokes E, Minocha M, Hashemi-Sadraei N, Shetty A, Smit M, Yang H, Owonikoko T. 359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results Journal For ImmunoTherapy Of Cancer 2020, 8: a384-a384. DOI: 10.1136/jitc-2020-sitc2020.0359.
  • Association Between Prophylactic Cranial Irradiation and Improved Overall Survival in Small Cell Lung CancerYang D, Park H, Jairam V, Decker R, Chiang A, Gross C, Yu J. Association Between Prophylactic Cranial Irradiation and Improved Overall Survival in Small Cell Lung Cancer International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e106. DOI: 10.1016/j.ijrobp.2020.07.1223.
  • Development and evaluation of patient reported outcomes-based performance measures during chemotherapy.Urick B, Stover A, Deal A, Jansen J, Chiang A, Cleeland C, Zylla D, Basch E. Development and evaluation of patient reported outcomes-based performance measures during chemotherapy. Journal Of Clinical Oncology 2020, 38: e19175-e19175. DOI: 10.1200/jco.2020.38.15_suppl.e19175.
  • Use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy.Yang D, Jairam V, Park H, Decker R, Chiang A, Gross C, Yu J. Use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy. Journal Of Clinical Oncology 2020, 38: e19309-e19309. DOI: 10.1200/jco.2020.38.15_suppl.e19309.
  • A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer.Lu M, Walia G, Schulze K, Doral M, Maund S, Gaffey S, Cabili M, Bourla A, Green R, Santos E, Herbst R, Chiang A, Schwartzberg L. A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer. Journal Of Clinical Oncology 2020, 38: tps2087-tps2087. DOI: 10.1200/jco.2020.38.15_suppl.tps2087.
  • Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).Owonikoko T, Borghaei H, Champiat S, Paz-Ares L, Govindan R, Boyer M, Johnson M, Udagawa H, Hummel H, Salgia R, Blackhall F, Boosman R, Lai W, Dowlati A, Vokes E, Hann C, Chiang A, Endraca M, Soman N, Smit M. Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC). Journal Of Clinical Oncology 2020, 38: tps9080-tps9080. DOI: 10.1200/jco.2020.38.15_suppl.tps9080.
  • ON5 DEVELOPMENT AND TESTING OF PATIENT-REPORTED OUTCOME PERFORMANCE MEASURES (PRO-PMS) FOR COMPARING ONCOLOGY PRACTICESStover A, Urick B, Deal A, Jansen J, Henson S, Miller R, Smith T, Scholle S, Chiang A, Cleeland C, Deutsch Y, Zylla D, Pitzen C, Snyder C, McNiff K, Krzyzanowska M, Spears P, Smith M, Geoghegan C, Basch E. ON5 DEVELOPMENT AND TESTING OF PATIENT-REPORTED OUTCOME PERFORMANCE MEASURES (PRO-PMS) FOR COMPARING ONCOLOGY PRACTICES Value In Health 2019, 22: s413. DOI: 10.1016/j.jval.2019.09.085.
  • Development and testing of patient-reported outcome performance measures (PRO-PMs) for oncology practice.Stover A, Urick B, Deal A, Jansen J, Henson S, Miller R, Smith T, Scholle S, Chiang A, Cleeland C, Deutsch Y, Zylla D, Pitzen C, Snyder C, McNiff K, Krzyzanowska M, Spears P, Smith M, Geoghegan C, Basch E. Development and testing of patient-reported outcome performance measures (PRO-PMs) for oncology practice. Journal Of Clinical Oncology 2019, 37: 173-173. DOI: 10.1200/jco.2019.37.27_suppl.173.
  • ASCO Quality Training Program: Five-year review.Keng M, Cunningham G, Gilmore T, Gilligan T, Quinn D, Kaufman L, Bingham J, Guerrier V, Chiang A, Mohamed A, Hagemann J. ASCO Quality Training Program: Five-year review. Journal Of Clinical Oncology 2019, 37: 7-7. DOI: 10.1200/jco.2019.37.27_suppl.7.
  • Benefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database.Dendy Case M, Dendy Case M, Uhlig J, Uhlig J, Blasberg J, Boffa D, Chiang A, Gettinger S, Kim H, Kim H. Benefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database. Journal Of Clinical Oncology 2019, 37: 8545-8545. DOI: 10.1200/jco.2019.37.15_suppl.8545.
  • 03:00 PM Abstract No. 278 Thermal ablation versus stereotactic radiation therapy for stage 4 lung cancer: contemporary trends and outcomes from the National Cancer DatabaseUhlig J, Uhlig J, Dendy M, Goldberg S, Chiang A, Blasberg J, Kim H, Kim H. 03:00 PM Abstract No. 278 Thermal ablation versus stereotactic radiation therapy for stage 4 lung cancer: contemporary trends and outcomes from the National Cancer Database Journal Of Vascular And Interventional Radiology 2019, 30: s124-s125. DOI: 10.1016/j.jvir.2018.12.342.
  • Standardizing goals of care (GoC) documentation for new patients with metastatic disease.Kidwai W, Engelking C, Pyle J, Chiang A. Standardizing goals of care (GoC) documentation for new patients with metastatic disease. Journal Of Clinical Oncology 2018, 36: 26-26. DOI: 10.1200/jco.2018.36.34_suppl.26.
  • Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or MelanomaCampbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s18-s19. DOI: 10.1016/j.ijrobp.2018.06.134.
  • Simple interventions to decrease use of chemotherapy in patients at the end of life.Chiang A, Adelson K, Kapo J, Severino K, Lilenbaum R. Simple interventions to decrease use of chemotherapy in patients at the end of life. Journal Of Clinical Oncology 2018, 36: 181-181. DOI: 10.1200/jco.2018.36.30_suppl.181.
  • Improved acute pain management in oncology patients using early scheduled contact with a pain coach.LaSala J, Chiang A, Severino K. Improved acute pain management in oncology patients using early scheduled contact with a pain coach. Journal Of Clinical Oncology 2018, 36: 293-293. DOI: 10.1200/jco.2018.36.30_suppl.293.
  • MA15.11 Real World Biomarker Testing and Treatment Patterns in Patients with Advanced NSCLC Receiving EGFR-TKIsChiang A, Fernandes A, Pavilack M, Wu J, Laliberté F, Duh M, Chehab N, Subramanian J. MA15.11 Real World Biomarker Testing and Treatment Patterns in Patients with Advanced NSCLC Receiving EGFR-TKIs Journal Of Thoracic Oncology 2018, 13: s410-s411. DOI: 10.1016/j.jtho.2018.08.447.
  • Abstract A09: Impaired HLA Class I antigen processing and presentation as a mechanism of acquired Rrsistance to immune checkpoint inhibitors in lung cancerHastings K, Gettinger S, Jungmin C, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick M, Schlessinger J, Goldberg S, Chiang A, Melero I, Agorreta J, Montuenga L, Lifton R, Ferrone S, Kavathas P, Rimm D, Kaech S, Schalper K, Herbst R, Politi K. Abstract A09: Impaired HLA Class I antigen processing and presentation as a mechanism of acquired Rrsistance to immune checkpoint inhibitors in lung cancer Cancer Immunology Research 2018, 6: a09-a09. DOI: 10.1158/2326-6074.tumimm17-a09.
  • Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Lilenbaum R, Jilaveanu L, Rowen E, Gerrish H, Komlo A, Wei W, Chiang V, Kluger H. Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. Journal Of Clinical Oncology 2018, 36: 2009-2009. DOI: 10.1200/jco.2018.36.15_suppl.2009.
  • Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma.Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma. Journal Of Clinical Oncology 2018, 36: 9099-9099. DOI: 10.1200/jco.2018.36.15_suppl.9099.
  • Chapter 7 A Practical Approach to Management of Small Cell Lung CancerTalsania A, Chiang A. Chapter 7 A Practical Approach to Management of Small Cell Lung Cancer 2018, 117-129. DOI: 10.1016/b978-0-323-48565-4.00007-2.
  • 1530PD Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)Daniel D, Rudin C, Hart L, Spigel D, Edelman M, Goldschmidt J, Bordoni R, Glisson B, Burns T, Dowlati A, Dy G, Beck T, Jotte R, Liu S, Kapoun A, Faoro L, Chiang A. 1530PD Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC) Annals Of Oncology 2017, 28: v540. DOI: 10.1093/annonc/mdx386.004.
  • Abstract 1727: Circulating Tumor Cells (CTCs) in patients with extensive stage small cell lung cancer and their association with clinical outcomeZhang C, Graf R, Jendrisak A, Anderson A, Ontiveros P, Orr S, Chiang A, Spigel D, Rudin C, Holmgren E, Dupont J, Argast G, Faoro L, Zhou L, Lewicki J, Kapoun A. Abstract 1727: Circulating Tumor Cells (CTCs) in patients with extensive stage small cell lung cancer and their association with clinical outcome Cancer Research 2017, 77: 1727-1727. DOI: 10.1158/1538-7445.am2017-1727.
  • Racial disparities in the use of programmed death-1 checkpoint inhibitors.O'Connor J, Seidl-Rathkopf K, Torres A, You P, Nussbaum N, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy A, Gross C. Racial disparities in the use of programmed death-1 checkpoint inhibitors. Journal Of Clinical Oncology 2017, 35: 3068-3068. DOI: 10.1200/jco.2017.35.15_suppl.3068.
  • Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer.Presley C, Soulos P, Chiang A, Longtine J, Adelson K, Herbst R, Nussbaum N, Sorg R, Abernethy A, Agarwala V, Gross C. Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer. Journal Of Clinical Oncology 2017, 35: 6563-6563. DOI: 10.1200/jco.2017.35.15_suppl.6563.
  • Adoption of immunotherapy into real-world practice: Insights from the use of checkpoint inhibitors.O'Connor J, Seidl-Rathkopf K, You P, Nussbaum N, Torres A, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy A, Gross C. Adoption of immunotherapy into real-world practice: Insights from the use of checkpoint inhibitors. Journal Of Clinical Oncology 2017, 35: e14583-e14583. DOI: 10.1200/jco.2017.35.15_suppl.e14583.
  • Hard-wiring survivorship care plan delivery.Barbarotta L, Jauk M, Chiang A, Sanft T. Hard-wiring survivorship care plan delivery. Journal Of Clinical Oncology 2017, 35: 113-113. DOI: 10.1200/jco.2017.35.8_suppl.113.
  • Comparison of initial and recertification QOPI scores: Maintaining compliance through direct surveyor and practice interaction.Chiang A, Barysauskas C, Conti-Kalchik T, Gilmore T, Hendricks C, Neuss M, Jacobson J. Comparison of initial and recertification QOPI scores: Maintaining compliance through direct surveyor and practice interaction. Journal Of Clinical Oncology 2017, 35: 246-246. DOI: 10.1200/jco.2017.35.8_suppl.246.
  • Challenges, barriers, and keys to success for sustainable quality improvement in oncology: A focus group of oncology quality leaders.Chiang A, Reeder-Hayes K, McNiff K, Evans T, Lennes I, Eaton E, Kamal A. Challenges, barriers, and keys to success for sustainable quality improvement in oncology: A focus group of oncology quality leaders. Journal Of Clinical Oncology 2017, 35: 78-78. DOI: 10.1200/jco.2017.35.8_suppl.78.
  • Should Cancer Centers start their own specialty pharmacy? Quality and economic data from the oral chemotherapy program at Smilow Cancer Hospital and Yale New Haven Health System.Adelson K, Stutsky M, Fradkin M, Harrison M, Abdelghany O, Morrow B, Smith M, Havriliak R, Kregling S, Lyons C, Chiang A, Cohen H. Should Cancer Centers start their own specialty pharmacy? Quality and economic data from the oral chemotherapy program at Smilow Cancer Hospital and Yale New Haven Health System. Journal Of Clinical Oncology 2017, 35: 108-108. DOI: 10.1200/jco.2017.35.8_suppl.108.
  • Cancer of the LungLu C, Morgensztern D, Chiang A, Onn A, Sepesi B, Vaporciyan A, Chang J, Komaki R, Wistuba I, Herbst R. Cancer of the Lung 2017, 1-30. DOI: 10.1002/9781119000822.hfcm085.
  • MA16.02 Mutational Landscape of TKI Naïve and Resistant EGFR Mutant Lung AdenocarcinomasHastings K, Hastings K, Choi J, Choi J, Wurtz A, Walther Z, Cai G, Oliva I, Oliva I, Zhao Z, Zhao Z, Gaffney S, Gaffney S, Iamarino A, Iamarino A, Zhao S, Zhao S, Bi M, Bi M, Goldberg S, Chiang A, Liu Z, Liu Z, Townsend J, Schlessinger J, Lifton R, Herbst R, Gettinger S, Politi K. MA16.02 Mutational Landscape of TKI Naïve and Resistant EGFR Mutant Lung Adenocarcinomas Journal Of Thoracic Oncology 2017, 12: s435. DOI: 10.1016/j.jtho.2016.11.507.
  • P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Topic: IT BiomarkersChoi J, Sowell R, Truini A, Schalper K, Wurtz A, Cai G, Perry C, Datar I, Hastings K, Melnick M, Kaftan E, Kavathas P, Kaech S, Rimm D, Goldberg S, Chiang A, Lifton R, Chen L, Herbst R, Politi K, Gettinger S. P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Topic: IT Biomarkers Journal Of Thoracic Oncology 2017, 12: s1331-s1332. DOI: 10.1016/j.jtho.2016.11.1884.
  • P3.02c-048 A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC Topic: ITDecker R, Goldberg S, Nath S, Husain Z, Lilenbaum R, Schalper K, Chiang A, Altan M, Zelterman D, Kaech S, Herbst R, Gettinger S. P3.02c-048 A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC Topic: IT Journal Of Thoracic Oncology 2017, 12: s1303-s1304. DOI: 10.1016/j.jtho.2016.11.1843.
  • Perspectives on the Use of Clinical Pathways in Oncology CareChiang A, Ellis P, Zon R. Perspectives on the Use of Clinical Pathways in Oncology Care American Society Of Clinical Oncology Educational Book 2017, 37: 155-159. DOI: 10.14694/edbk_175533.
  • 1425PD Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)Sequist L, Chiang A, Gilbert J, Gordon M, Conkling P, Thompson D, Marcoux J, Antonia S, Liu B, Shames D, Lopez-Chavez A, O'Hear C, Fasso M, Gettinger S. 1425PD Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC) Annals Of Oncology 2016, 27: vi493. DOI: 10.1093/annonc/mdw389.03.
  • Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors.Gettinger S, Zhang X, Homer R, Possick J, Wurtz A, Goldberg S, Chiang A, Herbst R, Rubinowitz A. Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors. Journal Of Clinical Oncology 2016, 34: 9030-9030. DOI: 10.1200/jco.2016.34.15_suppl.9030.
  • Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).Chiang A, Rudin C, Spira A, Jotte R, Gadgeel S, Mita A, Hart L, Gluck W, Liu S, Kapoun A, Xu L, Hill D, Zhou L, Dupont J, Spigel D. Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). Journal Of Clinical Oncology 2016, 34: 8564-8564. DOI: 10.1200/jco.2016.34.15_suppl.8564.
  • Objective measurement and significance of PD-L1, B7-H3, B7-H4 and TILs in small cell lung cancer (SCLC).Schalper K, Carvajal-Hausdorf D, McLaughlin J, Altan M, Chiang A, Velcheti V, Kaftan E, Zhang J, Lu L, Rimm D, Han B, Lu H, Zhao H, Herbst R. Objective measurement and significance of PD-L1, B7-H3, B7-H4 and TILs in small cell lung cancer (SCLC). Journal Of Clinical Oncology 2016, 34: 8566-8566. DOI: 10.1200/jco.2016.34.15_suppl.8566.
  • HER2 amplification in EGFR mutant NSCLC after acquired resistance (AR) to EGFR-directed therapies.Xia B, Wurtz A, Gettinger S, Herbst R, Chiang A, Wan M, Sklar J, Neumeister V, Politi K, Goldberg S. HER2 amplification in EGFR mutant NSCLC after acquired resistance (AR) to EGFR-directed therapies. Journal Of Clinical Oncology 2016, 34: 9049-9049. DOI: 10.1200/jco.2016.34.15_suppl.9049.
  • Carfilzomib (CFZ), carboplatin and etoposide for previously untreated extensive-stage small cell lung cancer (ES-SCLC): Phase 1b results from a phase 1b/2 study.Badin F, Chiang A, Fisher W, Orlov S, Harper H, Eskander E, Harb W, Kio E, Gopalan P, Haggstrom D, Burdaeva O, Zahlten-Kumeli A, Aggarwal S, Obreja M, Gorbunova V. Carfilzomib (CFZ), carboplatin and etoposide for previously untreated extensive-stage small cell lung cancer (ES-SCLC): Phase 1b results from a phase 1b/2 study. Journal Of Clinical Oncology 2016, 34: e20092-e20092. DOI: 10.1200/jco.2016.34.15_suppl.e20092.
  • Multidisciplinary process improvement to optimize oral chemotherapy safety.Amport S, Adelson K, Fradkin M, Havriliak R, Harrison M, Abdelghany O, Kregling S, Wright J, Morrow B, Sterling R, Smith M, Esposito F, Stutsky M, Miller L, Lilenbaum R, Lyons C, Chiang A, Cohen H. Multidisciplinary process improvement to optimize oral chemotherapy safety. Journal Of Clinical Oncology 2016, 34: 134-134. DOI: 10.1200/jco.2016.34.7_suppl.134.
  • ASCO PRO workgroup update: Patient-reported outcome measures as a quality indicator.Stover A, Chiang A, Basch E. ASCO PRO workgroup update: Patient-reported outcome measures as a quality indicator. Journal Of Clinical Oncology 2016, 34: 276-276. DOI: 10.1200/jco.2016.34.7_suppl.276.
  • Why the Quality Oncology Practice Initiative Matters: It’s Not Just About CostChiang A. Why the Quality Oncology Practice Initiative Matters: It’s Not Just About Cost American Society Of Clinical Oncology Educational Book 2016, 36: e102-e107. DOI: 10.14694/edbk_160113.
  • Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).Pietanza M, Spira A, Jotte R, Gadgeel S, Mita A, Hart L, Gluck W, Chiang A, Liu S, Kapoun A, Xu L, Hill D, Dupont J, Spigel D, Zhou L. Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). Journal Of Clinical Oncology 2015, 33: 7508-7508. DOI: 10.1200/jco.2015.33.15_suppl.7508.
  • Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases.Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Tsiouris A, Vortmeyer A, Jilaveanu L, Speaker S, Madura M, Rowen E, Gerrish H, Knapp-Perry E, Yao X, Chiang V, Kluger H. Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. Journal Of Clinical Oncology 2015, 33: 8035-8035. DOI: 10.1200/jco.2015.33.15_suppl.8035.
  • Development of Smilow's EPIC ambulatory dashboard and the impact on bar code scanning compliance at care centers.Amport S, Shomsky L, Lyons C, Sterling R, Smith M, Beaulieu N, Corjulo D, Adelson K, Chiang A. Development of Smilow's EPIC ambulatory dashboard and the impact on bar code scanning compliance at care centers. Journal Of Clinical Oncology 2014, 32: 166-166. DOI: 10.1200/jco.2014.32.30_suppl.166.
  • Characterization of aggressive interventions within 30 days of death in lung cancer patients at Smilow Cancer Hospital (SCH).Zhang B, Adelson K, Velji S, Rimar J, Longley P, Keane B, Chiang A, Lilenbaum R. Characterization of aggressive interventions within 30 days of death in lung cancer patients at Smilow Cancer Hospital (SCH). Journal Of Clinical Oncology 2014, 32: 20-20. DOI: 10.1200/jco.2014.32.30_suppl.20.
  • 1473P Phase 1B Trial of Anti-Notch 2/3 Antibody Omp-59R5 in Combination with Etoposide and Cisplatin (Ep) in Patients (Pts) with Untreated Extensive-Stage Small-Cell Lung Cancer (Ed-Sclc): the Pinnacle StudyPietanza M, Spira A, Jotte R, Gadgeel S, Mita A, Liu S, Gluck W, Kalemkerian G, Chiang A, Hart L, Kapoun A, Xu L, Hill D, Zhou L, Dupont J, Spigel D. 1473P Phase 1B Trial of Anti-Notch 2/3 Antibody Omp-59R5 in Combination with Etoposide and Cisplatin (Ep) in Patients (Pts) with Untreated Extensive-Stage Small-Cell Lung Cancer (Ed-Sclc): the Pinnacle Study Annals Of Oncology 2014, 25: iv514. DOI: 10.1093/annonc/mdu355.11.
  • Assessment of quality improvement efforts by ASCO’s Quality Oncology Practice Initiative (QOPI) participants.Chiang A, McNiff K, Kadlubek P, Neuss M, Joseph J. Assessment of quality improvement efforts by ASCO’s Quality Oncology Practice Initiative (QOPI) participants. Journal Of Clinical Oncology 2013, 31: 55-55. DOI: 10.1200/jco.2013.31.31_suppl.55.
  • Qualitative analysis of practicing oncologists’ attitudes and experiences regarding HIT-facilitated collection of patient-reported outcomes.Jagsi R, Chiang A, Medeiros B, Polite B, McNiff K, Zon R, Loehrer P. Qualitative analysis of practicing oncologists’ attitudes and experiences regarding HIT-facilitated collection of patient-reported outcomes. Journal Of Clinical Oncology 2012, 30: 56-56. DOI: 10.1200/jco.2012.30.34_suppl.56.
  • WNT/TCF Signaling through LEF1 and HOXB9 Mediates Lung Adenocarcinoma MetastasisNguyen D, Chiang A, Zhang X, Kim J, Kris M, Ladanyi M, Gerald W, Massagué J. WNT/TCF Signaling through LEF1 and HOXB9 Mediates Lung Adenocarcinoma Metastasis Journal Of End-to-End-testing 2009, 138: 51-62. DOI: 10.1016/s9999-9994(09)20363-1.

Clinical Trials

ConditionsStudy Title
LungRandomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
LungA Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
LungA Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
LungPhase 2 Trial of Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous Non-Small Cell Lung Cancer
LungA Phase I Study of ABBV-011 as a Single-Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Relapsed or Refractory Small Cell Lung Cancer
LungIntegration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
LungThe Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer
Lung; StomachA Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN) Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
LungPhase IB/II Trial Of Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
LungA Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy
Corpus Uteri; Larynx; Lung; Soft Tissue; Unknown SitesA Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors
LungLUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LungA Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
LungA Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)
Lung; Melanoma, skinA Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or LN-145) in Patients With Solid Tumors
LungDetermining Mechanisms of Sensitivity and Resistance to Anti-Cancer Therapy for Advanced Lung Cancer
LungA Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
LungAdjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Brain and Nervous System; Lung; Melanoma, skinA Phase II Trial of Pembrolizumab Plus Bevacizumab in Patients With Metastatic Melanoma or Non-small Cell Lung Cancer With Untreated Brain Metastases
LungA Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)